Clinical and economic consequences of ozenoxacin vs. other topical antibiotics for the treatment of impetigo: a real-life study in Spain.

IF 0.4 Q4 HEALTH CARE SCIENCES & SERVICES

Global & Regional Health Technology Assessment Pub Date : 2022-01-01 DOI:10.33393/grhta.2022.2439

Jaime Rodríguez-Quintosa, Cintia Cristina Ago, Antoni Sicras-Mainar, Renata Villoro, Inés Pérez-Román

{"title":"Clinical and economic consequences of ozenoxacin vs. other topical antibiotics for the treatment of impetigo: a real-life study in Spain.","authors":"Jaime Rodríguez-Quintosa, Cintia Cristina Ago, Antoni Sicras-Mainar, Renata Villoro, Inés Pérez-Román","doi":"10.33393/grhta.2022.2439","DOIUrl":null,"url":null,"abstract":"Background: Impetigo is a common dermatological paediatric infection that can be treated with topical antibiotics: the common are mupirocin (MUP), fusidic acid (FA) and, most recently, ozenoxacin (OZ).Aim: This study assesses the clinical and economic consequences of the use of OZ vs. MUP and vs. FA for the treatment of impetigo in routine clinical practice in Spain.Methods: This is a retrospective observational study using real-life data from electronic medical records of patients with impetigo who started treatment with OZ, MUP or FA (maximum follow-up: 3 months; n = 10,974). We compared treatment duration, comorbidities, use of systemic medication, complications, utilization of resources and associated costs across treatments (p<0.05). Cost-effectiveness of OZ was assessed from a social perspective. Complication rates and treatment duration were the effectiveness measures.Results: Mean age was 12.6 (standard deviation [SD]: 16.6) years; 48.6% were male; treatment: 9.3% (OZ), 56.4% (MUP), 34.5% (FA). The percentage of patients ending treatment after 2 weeks was 87.6% (OZ) vs. 83.2% (MUP) vs. 82.4% (FA); p<0.001; complication rates were 1.8% (OZ), 3.3% (MUP) and 3.2% (FA), p<0.001; mean costs were €158 (OZ), €265 (MUP) and €287 (FA), p<0.001.Conclusions: OZ is a cost-effective and dominant alternative for the treatment of impetigo.","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/67/f4/grhta-9-133.PMC9616209.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global & Regional Health Technology Assessment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33393/grhta.2022.2439","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 2

Abstract

Background: Impetigo is a common dermatological paediatric infection that can be treated with topical antibiotics: the common are mupirocin (MUP), fusidic acid (FA) and, most recently, ozenoxacin (OZ).

Aim: This study assesses the clinical and economic consequences of the use of OZ vs. MUP and vs. FA for the treatment of impetigo in routine clinical practice in Spain.

Methods: This is a retrospective observational study using real-life data from electronic medical records of patients with impetigo who started treatment with OZ, MUP or FA (maximum follow-up: 3 months; n = 10,974). We compared treatment duration, comorbidities, use of systemic medication, complications, utilization of resources and associated costs across treatments (p<0.05). Cost-effectiveness of OZ was assessed from a social perspective. Complication rates and treatment duration were the effectiveness measures.

Results: Mean age was 12.6 (standard deviation [SD]: 16.6) years; 48.6% were male; treatment: 9.3% (OZ), 56.4% (MUP), 34.5% (FA). The percentage of patients ending treatment after 2 weeks was 87.6% (OZ) vs. 83.2% (MUP) vs. 82.4% (FA); p<0.001; complication rates were 1.8% (OZ), 3.3% (MUP) and 3.2% (FA), p<0.001; mean costs were €158 (OZ), €265 (MUP) and €287 (FA), p<0.001.

Conclusions: OZ is a cost-effective and dominant alternative for the treatment of impetigo.

查看原文本刊更多论文

奥硝沙星与其他局部抗生素治疗脓疱疮的临床和经济后果:西班牙的一项现实研究。

背景:脓疱疮是一种常见的儿科皮肤感染，可以用局部抗生素治疗:常见的有莫匹罗星(MUP)、夫西地酸(FA)和最近的奥硝沙星(OZ)。目的:本研究评估了在西班牙常规临床实践中使用OZ与MUP和FA治疗脓疱疮的临床和经济后果。方法:这是一项回顾性观察性研究，使用电子病历中开始使用OZ、MUP或FA治疗的脓疱疮患者的真实数据(最长随访时间:3个月;N = 10,974)。我们比较了治疗时间、合并症、全身药物使用、并发症、资源利用和相关费用(结果:平均年龄为12.6岁(标准差[SD]: 16.6)岁;48.6%为男性;治疗组:9.3% (OZ)， 56.4% (MUP)， 34.5% (FA)。2周后结束治疗的患者比例为87.6% (OZ) vs. 83.2% (MUP) vs. 82.4% (FA);结论:奥兹是治疗脓疱疮的一种经济有效的替代方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Global & Regional Health Technology Assessment HEALTH CARE SCIENCES & SERVICES-

CiteScore

0.80

自引率

20.00%

发文量

审稿时长

8 weeks

期刊介绍： Global & Regional Health Technology Assessment (GRHTA) is a peer-reviewed, open access journal which aims to promote health technology assessment and economic evaluation, enabling choices among alternative therapeutical paths or procedures with different clinical and economic outcomes. GRHTA is a unique journal having three different editorial boards who focus on their respective geographical expertise.